Blog
RSS FeedPosted by Michael Wonder on 09 May 2025
Adagrasib for previously treated patients with advanced KRAS G12C mutation positive non-small-cell lung cancer
9 May 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 May 2025
DoH publishes revised agenda for the July 2025 PBAC meeting
9 May 2025 - The agenda for the July 2025 PBAC meeting has been updated. ...
Posted by Michael Wonder on 09 May 2025
Osimertinib mesylate in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy for patients with advanced EGFR mutation positive non-small-cell lung cancer (final guidance)
8 May 2025 - Osimertinib mesylate, when used in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy, is recommended as an ...
Posted by Michael Wonder on 08 May 2025
PHARMAC funds and widens access to melanoma medicines
9 May 2025 - PHARMAC is funding more medicines for people with skin cancer (melanoma), from 1 June 2025. ...
Posted by Michael Wonder on 08 May 2025
Brentuximab vedotin in combination with chemotherapy for the treatment of patients with stage 3 or 4 CD30 positive Hodgkin lymphoma
7 May 2025 - Brentuximab vedotin, when used in combination with doxorubicin hydrochloride, dacarbazine and vinblastine sulphate is recommended as an ...
Posted by Michael Wonder on 07 May 2025
Omaveloxolone for the treatment of patients with Friedreich’s ataxia
6 May 2025 - NICE is unable to make a recommendation on the use of omaveloxolone (Skyclarys) for the treatment of ...
Posted by Michael Wonder on 04 May 2025
Government lists life-changing epilepsy drug fenfluramine on PBS
4 May 2025 - For the Sutton family, finding a drug that controlled four-year-old daughter Layla’s rare form of epilepsy was ...
Posted by Michael Wonder on 02 May 2025
DoH publishes revised agenda for the May 2025 PBAC meeting
2 May 2025 - The agenda for the May 2025 PBAC meeting has been updated. ...
Posted by Michael Wonder on 01 May 2025
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
1 May 2025 - Our final draft guidance recommends linzagolix (Yselty, Theramex) with hormonal add-back therapy for adults of reproductive age ...
Posted by Michael Wonder on 30 Apr 2025
SMC - April 2025 decisions
7 April 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 28 Apr 2025
Come to grips’: fighting lymphoma from home
28 April 2025 - Australian patients with the most common form of lymphoma will for the first time have access ...
Posted by Michael Wonder on 28 Apr 2025
New position statement aims to guide the use of AI methods in health technology assessment
25 April 2025 - Canada’s Drug Agency has published a new position statement on the use of artificial intelligence methods ...
Posted by Michael Wonder on 27 Apr 2025
Ketamine nasal spray to become cheaper for Australians with treatment-resistant depression
28 April 2025 - A nasal spray that uses a form of ketamine to treat stubborn depression will be added ...
Posted by Michael Wonder on 27 Apr 2025
Dupilumab for the treatment of patients with moderate to severe chronic obstructive pulmonary disease
24 April 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 27 Apr 2025
Public Summary Documents (first time decisions not to recommend and deferrals) – December 2024 PBAC meeting
24 April 2025 - The Public Summary Documents (first-time decisions not to recommend and deferrals) from the December 2024 PBAC meeting ...